{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:59:14Z","timestamp":1777453154983,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:p>A concept of \u201call or nothing\u201d inspired the innovation of a one-pill-once-daily HIV treatment. Atripla\u00ae was the one pill that combined efavirenz, emtricitabine, and tenofovir disoproxil fumarate to become the first daily single tablet regimen that forever simplified HIV treatment to enhance patient compliance and thus, sustained viral suppression. The making of Atripla incorporated dry granulation and bilayer compression technologies to achieve stability and bioequivalence in an optimal pill size. In 2011, there lacked a standard of care for chronic hepatitis C infections that was safe, simple, short, free of interferon and ribavirin, and with high cure rates. A fixed-dose combination of ledipasvir and sofosbuvir was developed and approved in 2014 to be the first complete daily single tablet regimen for CHC genotype 1 infection. A spray-drying process for particle morphology engineering in a polymer matrix was used for improving bioavailability.<\/jats:p>","DOI":"10.1177\/13596535211067606","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T03:11:11Z","timestamp":1651461071000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["The making of the one pill\u2014Developing single tablet regimens for HIV and for HCV"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2465-0123","authenticated-orcid":false,"given":"Taiyin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Development and Manufacturing, Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Oliyai","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Development and Manufacturing, Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M","family":"Kent","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Development and Manufacturing, Gilead Sciences Inc, Foster City, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"bibr1-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.6.450"},{"key":"bibr2-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"bibr3-13596535211067606","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"bibr4-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07532-1"},{"key":"bibr5-13596535211067606","unstructured":"Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir (IDV) and\/or ritonavir (RTV) in an urban health clinic.\n                      37th International Conference on Antimicrobial Agents and Chemotherapy\n                      , 28 September 28\u20131 October 1997. Toronto, Ontario, Canada. Abstract LB-2."},{"key":"bibr6-13596535211067606","unstructured":"Stone VE, Adelson-Mitty J, Duefield CA, Steger KA, Stein MD, Mayer KH. Adherence to protease inhibitor (PI) therapy in clinical practice: usefulness of demographics, attitudes, and knowledge as predictors.\n                      12th World AIDS Conference (Geneva)\n                      . 1998, Stockholm: International AIDS Society: 588. Abstract 32337."},{"key":"bibr7-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1086\/322698"},{"key":"bibr8-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.24.1977"},{"key":"bibr9-13596535211067606","unstructured":"Klein R, Struble K. FDA Approves Atripla: the 1st 3-drug HAART pill contains Sustiva+Truvada (FTC+tenofovir). FDA News, July 12, 2006."},{"key":"bibr10-13596535211067606","author":"Dooren JC","year":"2006","journal-title":"Wall Street J"},{"key":"bibr11-13596535211067606","unstructured":"FDA Guidance for Industry\n                      . M9 Biopharmaceutics Classification System-Based Biowaivers. May 2021."},{"key":"bibr12-13596535211067606","unstructured":"Dahl TC, Hussain MA, Lipper RA, Jerzewski RL, Menning MM, Oliyai R, Yang T, inventors; Bristol-Myers Squibb & Gilead Sciences, Inc., assignee. Unitary pharmaceutical dosage form. United States patent US8598185. 2013 December 3."},{"key":"bibr13-13596535211067606","unstructured":"Pegasys (peginterferon alfa-2a). Package Insert 2002 and 2021. Hoffmann-La Roche, Inc. c\/o Genentech, Inc. South San Francisco, CA, USA."},{"key":"bibr14-13596535211067606","unstructured":"Incivek (telaprevir). Package Insert 2011. Vertex Pharmaceuticals, Inc. Boston, MA, USA."},{"key":"bibr15-13596535211067606","unstructured":"Copegus (ribavirin). Package Insert 2015. Hoffmann-La Roche, Inc. c\/o Genentech, Inc. South San Francisco, CA, USA."},{"key":"bibr16-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone"},{"key":"bibr17-13596535211067606","unstructured":"Harvoni (ledipasvir and sofosbuvir). Package Insert 2014. Gilead Sciences, Inc., Inc. Foster City, CA, USA."},{"key":"bibr18-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(96)00423-1"},{"key":"bibr19-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1016\/j.ddtec.2011.10.002"},{"key":"bibr20-13596535211067606","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21650"},{"key":"bibr21-13596535211067606","unstructured":"Moura C, Vicente J, Palha M, Neves F, Aguiar-Ricardo A, Costa E. Screening and optimization of formulation and process parameters for the manufacture of inhalable composite particles by spray-drying. Drug Delivery to the Lungs 25 Conference, December 10\u201312, 2014, Edinburgh, UK; Journal of Aerosol Medicine and Pulmonary Drug Delivery 2014; 74\u201377. 2015 July 31. Abstract 58."},{"key":"bibr22-13596535211067606","unstructured":"Mogalian E, Oliyai R, Stefanidis D, Zia V, inventors; Gilead Pharmasset LLC, Foster City, CA, USA, assignee. Solid dispersion formulation of an antiviral compound. World Intellectual Property Organization, International Publication No. WO2014\/120982 A1. 2014, August 7."},{"key":"bibr23-13596535211067606","unstructured":"Chal B, Mogalian E, Pakdaman R, Oliyai R, Stefanidis D, Zia V, inventors; Gilead Pharmasset LLC, Foster City, CA, USA, assignee. Combination formulation of two antiviral compounds. World Intellectual Property Organization, International Publication No. WO2014\/120981 A1. 2014, August 7."},{"key":"bibr24-13596535211067606","unstructured":"https:\/\/www.acs.org\/content\/acs\/en\/pressroom\/newsreleases\/2015\/june\/heroes-of-chemistry-developed-products-that-improve-health-homes-and-automobiles."},{"key":"bibr25-13596535211067606","unstructured":"Epclusa (sofosbuvir and velpatasvir). Package Insert 2016. Gilead Sciences, Inc., Inc. Foster City, CA, USA."}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211067606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13596535211067606","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13596535211067606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:53:05Z","timestamp":1777380785000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13596535211067606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1177\/13596535211067606"],"URL":"https:\/\/doi.org\/10.1177\/13596535211067606","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4]]},"article-number":"13596535211067606"}}